Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Development of a vaccine against pandemic influenza viruses: current status and perspectives.

Ilyinskii PO, Thoidis G, Shneider AM.

Int Rev Immunol. 2008;27(6):392-426. doi: 10.1080/08830180802295765. Review.

PMID:
19065349
2.

DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus.

Szécsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset FL.

J Infect Dis. 2009 Jul 15;200(2):181-90. doi: 10.1086/599840.

3.

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.

Vaccine. 2009 Oct 23;27(45):6276-9. doi: 10.1016/j.vaccine.2009.04.074.

PMID:
19840660
4.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB.

J Virol. 2009 May;83(9):4624-30. doi: 10.1128/JVI.02335-08. Epub 2009 Feb 11.

5.

A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.

Wu Q, Fang L, Wu X, Li B, Luo R, Yu Z, Jin M, Chen H, Xiao S.

Mol Immunol. 2009 Jul;46(11-12):2210-7. doi: 10.1016/j.molimm.2009.04.017. Epub 2009 May 14.

PMID:
19446339
6.
7.

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

Vaccine. 2009 Oct 23;27(45):6296-9. doi: 10.1016/j.vaccine.2009.03.020.

PMID:
19840663
8.

[Pandemic influenza vaccines: from the lab to ethical policy making].

Grotto I, Levine H, Balicer RD.

Harefuah. 2009 Oct;148(10):672-6, 735. Hebrew.

PMID:
20073393
9.

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

Park KS, Lee J, Ahn SS, Byun YH, Seong BL, Baek YH, Song MS, Choi YK, Na YJ, Hwang I, Sung YC, Lee CG.

Virology. 2009 Dec 20;395(2):182-9. doi: 10.1016/j.virol.2009.09.018.

10.

A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.

Xie H, Liu TM, Lu X, Wu Z, Belser JA, Katz JM, Tumpey TM, Ye Z.

J Infect Dis. 2009 Dec 15;200(12):1874-83. doi: 10.1086/648405.

11.

Designing vaccines for pandemic influenza.

Horimoto T, Kawaoka Y.

Curr Top Microbiol Immunol. 2009;333:165-76. doi: 10.1007/978-3-540-92165-3_8. Review.

PMID:
19768405
12.

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.

Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, Kong WP, Tumpey TM, Epstein SL.

Vaccine. 2008 Apr 16;26(17):2062-72. doi: 10.1016/j.vaccine.2008.02.047. Epub 2008 Mar 13.

PMID:
18378366
13.

Pandemic influenza vaccines.

DiMenna LJ, Ertl HC.

Curr Top Microbiol Immunol. 2009;333:291-321. doi: 10.1007/978-3-540-92165-3_15. Review.

PMID:
19768412
14.

Current status and progress of prepandemic and pandemic influenza vaccine development.

Leroux-Roels I, Leroux-Roels G.

Expert Rev Vaccines. 2009 Apr;8(4):401-23. doi: 10.1586/erv.09.15. Review.

PMID:
19348557
15.

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007.

Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D.

Vaccine. 2008 Aug 12;26(34):4299-303. doi: 10.1016/j.vaccine.2008.06.012. Epub 2008 Jun 26.

PMID:
18582523
16.

The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.

Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J.

Vaccine. 2008 Feb 13;26(7):956-65. doi: 10.1016/j.vaccine.2007.11.052. Epub 2007 Dec 10.

PMID:
18164519
17.

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP.

Plant Biotechnol J. 2008 Dec;6(9):930-40. doi: 10.1111/j.1467-7652.2008.00384.x.

18.

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR.

Hum Vaccin. 2007 Sep-Oct;3(5):157-64. Epub 2007 Mar 20.

PMID:
17637571
19.

Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes.

Zhang W, Li W, Li Y, Li H, Wang B, Wang F, Zhu Y, Jiang Z, Zhong L, Li M.

J Med Microbiol. 2009 Jul;58(Pt 7):845-54. doi: 10.1099/jmm.0.006825-0. Epub 2009 Jun 4.

PMID:
19498203
20.

Recombinant vaccines for influenza virus.

Tripp RA, Tompkins SM.

Curr Opin Investig Drugs. 2008 Aug;9(8):836-45. Review.

PMID:
18666031
Items per page

Supplemental Content

Write to the Help Desk